Arcturus Therapeutics

Update in progress

ARCT (NasdaqGM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Arcturus Therapeutics Holdings Inc. is a San Diego‑based messenger RNA medicines company focused on liver and respiratory rare diseases. Its STARR self‑amplifying mRNA platform and LUNAR lipid delivery system support programs such as ARCT-032 (LUNAR-CF) for cystic fibrosis in Phase 2, ARCT-810 (LUNAR-OTC) for OTC deficiency in Phase 2, KOSTAIVE (COVID-19 vaccine), ARCT-2138 (LUNAR-FLU) in Phase 1, and ARCT-2304 (LUNAR-H5N1) in Phase 1 for pandemic flu.

Company score

Sentiment: 0.26; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.22; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.11; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.09; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.17; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive